John Round

I lead Biotica Bio’s evidence-led target validation and diligence work, translating complex biology and platform evidence into decision-ready strategy for investors and enterprise healthcare stakeholders.

Strategic focus

Biotech and pharma target validation strategy.
Investor and executive due diligence framing.
Portfolio triage and indication prioritisation.
Reproducible evidence workflows using Open Targets.
Clinical, commercial, and adoption framing for payer/provider-adjacent innovation.

Background highlights

Life sciences investment and venture evaluation at Slater Technology Fund.
Entrepreneur-in-residence support for regional biotech company building.
Venture and platform strategy roles spanning Flagship Ventures-era venture labs and startup environments.
Early-career operating exposure in manufacturing and commercialization, translating science into execution.
Cross-domain operator experience including gemflush.com and placebo-rx.com, reinforcing practical execution discipline applied to life-sciences strategy.

Cross-domain execution context

gemflush.com: An AI discoverability platform that helps businesses get published to public knowledge graphs and then monitors recommendation visibility across assistants like ChatGPT, Claude, and Perplexity. Its knowledge-graph publishing model is inspired by open biomedical Wikidata curation patterns (entity completeness, provenance, and update discipline), adapted to commercial entity discoverability and recommendation performance.
placebo-rx.com: A digital wellness concept for chronic pain centered on open-label placebo rituals, multi-sensory engagement, and transparent, AI-assisted self-care feedback. The model is explicitly ethical (“no deception”) and explores how expectation, ritual, and interface design can influence perceived symptom relief.
Why this is valuable in venture and life sciences: Together, these projects show an operator lens that spans technical systems, behavior design, and commercialization: building practical products, validating adoption signals, and translating complex mechanisms into user-facing value propositions that can be tested, measured, and iterated.

Strategic operating approach

Evaluates opportunities through both scientific validity and healthcare system adoption feasibility.
Frames investment decisions around outcome impact, execution risk, and scalable commercialization pathways.
Bridges diligence outputs for venture teams, corporate strategy leaders, and operating stakeholders.

How I contribute

Decision strengths: Scientific diligence, commercialization pressure-testing, and portfolio triage.
Operating value: Connects technical evidence to adoption, reimbursement context, and execution milestones.
Collaboration style: Works effectively across investment, clinical, product, and strategy/BD stakeholders.
Typical outcomes: Clearer conviction thresholds, explicit risk framing, and more practical execution sequencing.

Full profile: LinkedIn.

For a concise overview of this strategic lens, see Venture operator profile.

Representative work

Sectors

For consulting scope, proposal, and delivery timeline, use Contact.